Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.


Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2024
Historique:
received: 21 04 2023
accepted: 02 07 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

Numerous aspects of cellular signaling are regulated by the kinome-the network of over 500 protein kinases that guides and modulates information transfer throughout the cell. The key role played by both individual kinases and assemblies of kinases organized into functional subnetworks leads to kinome dysregulation driving many diseases, particularly cancer. In the case of pancreatic ductal adenocarcinoma (PDAC), a variety of kinases and associated signaling pathways have been identified for their key role in the establishment of disease as well as its progression. However, the identification of additional relevant therapeutic targets has been slow and is further confounded by interactions between the tumor and the surrounding tumor microenvironment. In this work, we attempt to link the state of the human kinome, or kinotype, with cell viability in treated, patient-derived PDAC tumor and cancer-associated fibroblast cell lines. We applied classification models to independent kinome perturbation and kinase inhibitor cell screen data, and found that the inferred kinotype of a cell has a significant and predictive relationship with cell viability. We further find that models are able to identify a set of kinases whose behavior in response to perturbation drive the majority of viability responses in these cell lines, including the understudied kinases CSNK2A1/3, CAMKK2, and PIP4K2C. We next utilized these models to predict the response of new, clinical kinase inhibitors that were not present in the initial dataset for model devlopment and conducted a validation screen that confirmed the accuracy of the models. These results suggest that characterizing the perturbed state of the human protein kinome provides significant opportunity for better understanding of signaling behavior and downstream cell phenotypes, as well as providing insight into the broader design of potential therapeutic strategies for PDAC.

Identifiants

pubmed: 39221276
doi: 10.7717/peerj.17797
pii: 17797
pmc: PMC11365483
doi:

Substances chimiques

Protein Kinases EC 2.7.-
Protein Kinase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17797

Informations de copyright

©2024 Berginski et al.

Déclaration de conflit d'intérêts

Shawn M. Gomez is an Academic Editor for PeerJ.

Auteurs

Matthew E Berginski (ME)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.

Madison R Jenner (MR)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Chinmaya U Joisa (CU)

Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, United States of America.

Gabriela Herrera Loeza (G)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Brian T Golitz (BT)

Eshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Matthew B Lipner (MB)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Jack R Leary (JR)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Department of Biostatistics, University of Florida, Gainsville, FL, United States of America.

Naim Rashid (N)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Gary L Johnson (GL)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Jen Jen Yeh (JJ)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.

Shawn M Gomez (SM)

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH